# US 2013/0251791 A1 · Composition comprising a benzimidazole and process for its manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251791 A1
- Document ID: US20130251791A1
- Status: Published application
- Kind: A1
- Application number: 13/895,492
- Filed: 2013-05-16
- Published: 2013-09-26
- Earliest claimed: 2004-07-29
- Assignees: Ucb, S.A.
- Inventors: Pawan Seth; Benoit Schmitt
- Web page: https://patentgrep.com/patent/US20130251791A1

## CPC

- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) a core that is free of binder and free of PVP as a binder and/or HPMC;
(b) an intermediate layer; and
(c) an enteric layer;
wherein the core consists essentially of, by weight:
about 10 to about 80 parts of a benzimidazole active ingredient in an alkaline salt form,
about 20 to about 85 parts of a first, water-soluble, diluent,
0 to about 80 parts of a second, water-insoluble, diluent,
about 10 to about 40 parts of a disintegrant, and
0 to about 5 parts of a lubricant.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the second, water-insoluble, diluent is present in an amount up to about 80 parts, by weight.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the core consists essentially of, by weight:
about 15 to about 60 parts of said benzimidazole active ingredient,
about 40 to about 75 parts of the first, water-soluble, diluent,
up to about 40 parts of the second, water-insoluble, diluent,
about 15 to about 30 parts of the disintegrant, and
about 0.5 to about 5 parts of the lubricant.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the first diluent and the second diluent are present in a weight ratio of about 1.5:1 to 1:1.5.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the first, water-soluble, diluent comprises lactose and the second, water-insoluble, diluent comprises cellulose acetate.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the disintegrant comprises cross-linked polyvinylpyrrolidone.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the core consists essentially of, by weight:
about 15 to about 60 parts of said benzimidazole active ingredient,
about 40 to about 75 parts of lactose as the first, water-soluble, diluent,
about 15 to about 30 parts of the disintegrant, and
about 0.5 to about 5 parts of the lubricant.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the disintegrant comprises cross-linked polyvinylpyrrolidone.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises omeprazole in an alkaline salt form.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises esomeprazole in an alkaline salt form.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises pantoprazole in an alkaline salt form.

### Claim 12 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises lansoprazole in an alkaline salt form.

### Claim 13 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises rabeprazole in an alkaline salt form.

### Claim 14 (depends on 1)

The composition of claim 1, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 15 (depends on 2)

The composition of claim 2, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 16 (depends on 7)

The composition of claim 7, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 17 (depends on 9)

The composition of claim 9, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 18 (depends on 10)

The composition of claim 10, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 19 (depends on 11)

The composition of claim 11, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 20 (depends on 12)

The composition of claim 12, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 21 (depends on 13)

The composition of claim 13, provided either in a single tablet form or in the form of micro-tablets enclosed inside a capsule.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the benzimidazole active ingredient and the at least one excipient have been wet-granulated.

### Claim 23 (depends on 1)

The composition of claim 1, wherein the core comprises, by weight:
about 10 to about 80 parts of the benzimidazole active ingredient,
about 20 to about 85 parts of a first, water-soluble, diluent, and
about 10 to about 40 parts of a disintegrant.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the core further comprises up to about 80 parts by weight of a second, water-insoluble, diluent, and wherein the first diluent and the second diluent are present in a weight ratio of about 1.5:1 to 1:1.5.

### Claim 25 (depends on 23)

The composition of claim 23, wherein the core further comprises up to about 80 parts by weight of a second, water-insoluble, diluent, and wherein said first, water-soluble, diluent comprises lactose and said second, water-insoluble, diluent comprises cellulose acetate.

### Claim 26 (depends on 23)

The composition of claim 23, wherein the disintegrant comprises cross-linked polyvinylpyrrolidone.

### Claim 27 (depends on 23)

The composition of claim 23, wherein the lubricant comprises sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate or a mixture thereof.

### Claim 28 (depends on 23)

The composition of claim 23, wherein the core comprises, by weight:
about 15 to about 60 parts of said benzimidazole active ingredient,
about 40 to about 75 parts of lactose as the first, water-soluble, diluent,
about 15 to about 30 parts of a disintegrant, and
about 0.5 to about 5 parts of a lubricant.

### Claim 29 (depends on 23)

The composition of claim 23, wherein the core further comprises a filler, plastifier, surfactant, pigment, wetting agent, or mixture thereof.

### Claim 30 (depends on 1)

The composition of claim 1, wherein the benzimidazole active ingredient comprises omeprazole, esomeprazole, pantoprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, timoprazole, aripiprazole, diapiprazole, or a mixture thereof, each in an alkaline salt form.

### Claim 31 (depends on 2)

The composition of claim 2, wherein the core additionally comprises at least one further excipient that is other than a binder.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the at least one further excipient comprises a filler, plastifier, surfactant, pigment, wetting agent, or mixture thereof.

### Claim 33 (depends on 2)

The composition of claim 2, wherein the lubricant comprises sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate, or a mixture thereof.

### Claim 34 (depends on 2)

The composition of claim 2, wherein the benzimidazole active ingredient comprises omeprazole, esomeprazole, pantoprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, timoprazole, aripiprazole, diapiprazole, or a mixture thereof, each in an alkaline salt form.

### Claim 35 (depends on 7)

The composition of claim 7, wherein the core additionally comprises at least one further excipient that is other than a binder.

### Claim 36 (depends on 7)

The composition of claim 7, wherein the lubricant comprises sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate, or a mixture thereof.

### Claim 37 (depends on 7)

The composition of claim 7, wherein the benzimidazole active ingredient comprises omeprazole, esomeprazole, pantoprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, timoprazole, aripiprazole, diapiprazole, or a mixture thereof, each in an alkaline salt form.

### Claim 38 (depends on 1)

The composition of claim 1, wherein the benzimidazole active ingredient comprises a sodium salt of pantoprazole.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the sodium salt of pantoprazole comprises pantoprazole sodium sesquihydrate.

### Claim 40

A process for preparing a core that comprises, by weight:
about 10 to about 80 parts of a benzimidazole active ingredient,
about 20 to about 85 parts of a first, water-soluble, diluent,
0 to about 80 parts of a second, water-insoluble, diluent,
about 10 to about 40 parts of a disintegrant, and
0 to about 5 parts of a lubricant;
said process comprising
(i) wet granulating said active ingredient with said diluents, said disintegrant and said lubricant if any, in a high shear mixer in the absence of binder; and
(ii) compressing the product of step (i) to form a core free of binder.

### Claim 41 (depends on 40)

The process of claim 40, wherein the core consists essentially of, by weight:
about 15 to about 60 parts of said benzimidazole active ingredient,
about 40 to about 75 parts of the first, water-soluble, diluent,
0 to about 40 parts of the second, water-insoluble, diluent,
about 15 to about 30 parts of the disintegrant, and
0 to about 5 parts of the lubricant.

### Claim 42 (depends on 40)

The process of claim 40, wherein said wet granulating comprises the following sub-steps:
(a) dry mixing said benzimidazole active ingredient, said first diluent and optionally said second diluent and optionally part of said disintegrant;
(b) granulating the product of sub-step (a) with water to form granulates;
(c) drying the granulates of sub-step (b); and
(d) dry mixing the dried granulates of sub-step (c) with said disintegrant or the remainder thereof and said lubricant, if any.

### Claim 43

A process for preparing a composition that comprises:
(a) a core that consists essentially of, by weight:
about 15 to about 60 parts of a benzimidazole active ingredient,
about 40 to about 75 parts of lactose,
about 15 to about 30 parts of a disintegrant, and
about 0.5 to about 5 parts of a lubricant;
(b) an intermediate layer; and
(c) an enteric layer;
said process comprising
(i) wet granulating said active ingredient with said lactose, said disintegrant and said lubricant, in a high shear mixer in the absence of binder;
(ii) compressing the product of step (i) to form a tablet core free of binder;
(iii) coating said core with said intermediate layer; and
(iv) coating the product of step (iii) with said enteric layer.

### Claim 44 (depends on 43)

The process of claim 43, wherein said wet granulating comprises the following sub-steps:
(a) dry mixing said benzimidazole active ingredient, said lactose and optionally part of said disintegrant;
(b) granulating the product of sub-step (a) with water to form granulates;
(c) drying the granulates of sub-step (b); and
(d) dry mixing the dried granulates of sub-step (c) with said disintegrant or the remainder thereof and said lubricant.

### Claim 45 (depends on 40)

The process of claim 40, wherein the core comprises a second, water-insoluble, diluent, and wherein the weight ratio of the first diluent to the second diluent is from about 1.5:1 to 1:1.5.

### Claim 46 (depends on 40)

The process of claim 40, wherein the core comprises a second, water-insoluble, diluent, and wherein said first, water-soluble, diluent is lactose and said second, water-insoluble, diluent is cellulose acetate.

### Claim 47 (depends on 40)

The process of claim 40, wherein said disintegrant comprises cross-linked polyvinylpyrrolidone.

### Claim 48 (depends on 40)

The process of claim 40, wherein said lubricant comprises sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate or a mixture thereof.

### Claim 49 (depends on 40)

The process of claim 40, wherein the core consists essentially of, by weight:
about 15 to about 60 parts of said benzimidazole active ingredient,
about 40 to about 75 parts of lactose as the first, water-soluble diluent,
about 15 to about 30 parts of the disintegrant, and
about 0.5 to about 5 parts of the lubricant.

### Claim 50 (depends on 40)

The process of claim 40, further comprising:
(iii) coating said core with an intermediate layer; and
(iv) coating the product of step (iii) with an enteric layer.

### Claim 51 (depends on 40)

The process of claim 40, wherein the core additionally comprises at least one further excipient that is other than a binder.

### Claim 52 (depends on 51)

The process of claim 51, wherein the at least one further excipient comprises a filler, plastifier, surfactant, pigment, wetting agent, or mixture thereof.

### Claim 53 (depends on 43)

The process of claim 43, wherein the core additionally comprises at least one further excipient that is other than a binder.
